The clinical hold placed on Ziopharm's third generation point-of-care CAR-T program is unlikely to bring a significant delay, H.C. Wainwright analyst Swayampakula Ramakanth tells investors in a research note. The analyst views yesterday's 18% share pullback as a buying opportunity and reiterates a Buy rating on Ziopharm with a $5.50 price target. He notes that neither of the Ziopharm's clinical programs on Ad-RTS-hIL-12 or second generation CD19 and CD33 CAR-Ts has been affected by the clinical hold. The clinical hold is more akin to the FDA putting a "pause" on the investigational new drug application review process while the company prepares the response, Ramakanth argues.